Table 3.

Correlates of the speed of platelet engraftment excluding patients with early grade II–IV acute GVHD

	No. of patients	Slow platelet engraftment	Univariate analysis
	N = 106	(%)	OR	95% CI	P-value
Disease status at transplantation
Active disease with circulating blasts	31	77	5.6	1.9–16.4	0.002
Active disease without circulating blasts	38	60	2.5	0.99–6.4	0.05
CR	37	38	1.0	NA
Donor/patient CMV serostatus
Non-reactive/non-reactive	10	30	NA
Reactive/non-reactive	6	17	NA
Reactive/reactive	48	69	NA
Non-reactive/reactive	38	53	NA
Patient R/vs all other			4.8	1.4–16.2	0.01
Number of previous chemotherapy regimens
At least the median	38	68	2.0	0.9–4.7	0.09
Less than the median	68	51	1.0	NA
Age, years
At least 55	56	66	2.1	0.96–4.6	0.06
Less than 55	50	48	1.0	NA
Patient sex
Female	42	45	0.4	0.2–0.96	0.04
Male	64	66	1.0	NA
Donor/patient sex match
M/M	38	63	1.0	NA
F/F	15	33	0.3	0.1–0.96	0.04
M/F	27	52	1.0	NA
F/M	25	72	1.0	NA
Karyotype risk group
High	40	62	1.4	0.6–3.2	0.4
Intermediate	59	54	1.0	NA
Low	4	75
Unknown	3	33
Dose of melphalan, mg/m2
100	20	35	0.3	0.1–0.9	0.03
140/180	86	63	1.0	NA
Mylotarg
Yes	10	70	1.8	0.4–7.4	0.4
No	96	56	1.0	NA
Use of ATG in conditioninga
Yes	18	61	1.2	0.4–3.9	0.8
No	30	57	1.0	NA
Post-SCT day +30 ALC
Less than 500 × 106/l	39	72	2.6	1.1–6.1	0.03
At least 500 × 106/l	67	49	1.0

Abbreviations: CI = confidence interval; F = female; M = male; MSD = matched sibling donor; MUD = matched unrelated donor; NA = not applicable; OR = odds ratio; PB = peripheral blood; R = reactive.

Early acute GVHD refers to acute GVHD diagnosed before post transplant day +30.

Slow platelet engraftment is defined as occurring at or after post-SCT day + 15 in recipients of a MSD/PB graft, and at or after day +21 in recipients of a BM/MUD graft.

Totals are less than 106 for some variables because of missing data.

^aAmong recipients of a BM graft.